THURSDAY, Jan. 12 (HealthDay News) -- The chemotherapy used to
treat a form of adult leukemia sets a trap that can result in the
return of the disease within years, a new study suggests.
The finding confirms the suspicions of specialists who thought
chemotherapy drugs could disrupt DNA through mutations and
ultimately allow tumor cells to avoid the effects of the
"Chemotherapy drugs are absolutely necessary to get leukemia patients into remission, but we also pay a price in terms of DNA damage," study co-author Dr. Timothy Ley, a professor of oncology at Washington University School of Medicine in St. Louis, said in a university news release.
These drugs "may contribute to disease progression and relapse
in many different cancers, which is why our long-term goal is to
find targeted therapies based on the mutations specific to a
patient's cancer, rather than use drugs that further damage DNA,"
The type of leukemia in question is known as acute myeloid
leukemia. While chemotherapy treatment can send the cancer into
remission, 80 percent of patients die within five years. In the
United States, about 13,000 cases of acute myeloid leukemia are
diagnosed annually, most often in people age 60 and older.
The researchers came to their conclusions after studying the
genomes -- the entire DNA, both healthy and cancerous cells -- from
eight patients with acute myeloid leukemia. They watched to see
what happened after the patients received chemotherapy.
The investigators found that tumors essentially reappeared,
according to the report published in the Jan. 11 advance online
"It's the same tumor coming back but with a twist," co-author Richard Wilson, director of university's Genome Institute, explained in the news release. It "comes back with new mutations that give the cells new strategies for surviving attack by whatever drugs are thrown at them. This makes a lot of sense but it's been hard to prove without whole-genome sequencing."
Commenting on the report, Louis DeGennaro, executive vice
president and chief mission officer of the Leukemia & Lymphoma
Society, said the study "demonstrates the critical need to identify
disease-causing mutations in acute myeloid leukemia so that
therapies targeted specifically at these mutations can be
Ultimately, he added, "that would allow us to avoid the use of
chemotherapy, which may contribute to cancer relapse."
For now, DeGennaro said, "while current chemotherapy regimens
have liabilities, they represent the best treatment currently
available and may result in complete remission, which would allow
eligible patients to receive a stem cell transplant, the only
treatment capable of curing acute myeloid leukemia."
For more about
acute myeloid leukemia, visit the U.S. National Library of Medicine.